 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...459460461462463464465466467468469...522523» |
- | Bexxar (iodine I 131 tositumomab) / GSK, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date, Metastases: Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma (clinicaltrials.gov) - Sep 11, 2018
P1/2, N=96, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) - Sep 10, 2018
P2, N=23, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Trial primary completion date: Jun 2018 --> Dec 2018
- | Journal: High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. (Pubmed Central) - Sep 7, 2018
Conclusion BuMel improved EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide induction in localized ES with predefined high-risk factors. For this group of patients, BuMel may be an important addition to the standard of care.
- | Opdivo (nivolumab) / BMS
Trial initiation date: Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas (clinicaltrials.gov) - Sep 7, 2018
P1/2, N=18, Not yet recruiting, Sponsor: University of Colorado, Denver
For this group of patients, BuMel may be an important addition to the standard of care. Initiation date: Aug 2018 --> Nov 2018
- | Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci, Oncaspar liquid (pegaspargase) / Servier
Trial completion: AALL07P4: Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2018
P=N/A, N=166, Completed, Sponsor: Children's Oncology Group
Initiation date: Aug 2018 --> Nov 2018 Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 5, 2018
P2, N=39, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial completion date: Aug 2018 --> Aug 2019 | Trial primary completion date: Aug 2018 --> Aug 2019
- | doxorubicin hydrochloride / Generic mfg.
Journal: Enhanced Drug Delivery to the Skin Using Liposomes. (Pubmed Central) - Sep 4, 2018
In an in vivo model, LTSLs containing doxorubicin (dox) as a marker were administered intravenously to rats that were exposed locally to mild hyperthermia...Development of more hydrophilic immunosuppressants in the future would increase the applicability of this system in the treatment of rejection reactions in vascularized composite allotransplantation. The treatment of other skin condition might be another potential application.
- | Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment closed, Enrollment change, Trial primary completion date: Procarbazine Hydrochloride Capsule (Natulan (clinicaltrials.gov) - Sep 4, 2018
P=N/A, N=92, Active, not recruiting, Sponsor: Lee's Pharmaceutical Limited
The treatment of other skin condition might be another potential application. Not yet recruiting --> Active, not recruiting | N=184 --> 92 | Trial primary completion date: Feb 2020 --> Dec 2018
- | doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Does doxorubicin survive thermal ablation? Results of an ex vivo bench top study. (Pubmed Central) - Sep 2, 2018
Contrary to the initial hypothesis, tissue DOX concentration progressively decreased after MWA of longer ablation times. These results suggest that TACE followed by ablation may result in lower intratumoral DOX than would otherwise be anticipated for TACE alone.
- | doxorubicin hydrochloride / Generic mfg.
Trial termination: Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 31, 2018
P=N/A, N=6, Terminated, Sponsor: Weill Medical College of Cornell University
These results suggest that TACE followed by ablation may result in lower intratumoral DOX than would otherwise be anticipated for TACE alone. Completed --> Terminated; The study was terminated due to lack of accrual.
- | Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, Combination therapy: SELENE : A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 31, 2018
P3, N=403, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Completed --> Terminated; The study was terminated due to lack of accrual. Trial primary completion date: Jul 2019 --> Jul 2020
- | Rituxan (rituximab) / Roche
Trial primary completion date: Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma (clinicaltrials.gov) - Aug 31, 2018
P1/2, N=36, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2019 --> Jul 2020 Trial primary completion date: Oct 2025 --> Oct 2022
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Combination therapy, Metastases: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. (clinicaltrials.gov) - Aug 29, 2018
P2, N=69, Completed, Sponsor: MolMed S.p.A.
Trial primary completion date: Oct 2025 --> Oct 2022 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> May 2016
- | Arenegyr (NGR-hTNF) / AGC Biologics
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: NGR007: Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma (clinicaltrials.gov) - Aug 29, 2018
P2, N=28, Completed, Sponsor: MolMed S.p.A.
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> May 2016 Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2015 | Trial primary completion date: Jun 2016 --> Nov 2015
- | doxorubicin hydrochloride / Generic mfg.
Enrollment closed: ReChiVe: Prospective Multicentric Evaluation of a Bladder Preservation Strategy (clinicaltrials.gov) - Aug 29, 2018
P2, N=77, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Active, not recruiting --> Completed | Trial completion date: Jun 2016 --> Nov 2015 | Trial primary completion date: Jun 2016 --> Nov 2015 Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Aug 29, 2018
P2, N=401, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Aug 2020
- | entospletinib (GS-9973) / Kronos Bio, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy (clinicaltrials.gov) - Aug 29, 2018
P1/2, N=131, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Trial completion date: Dec 2020 --> Aug 2020 Trial primary completion date: Jun 2018 --> Apr 2020
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial initiation date, Combination therapy: NEMIO: NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (clinicaltrials.gov) - Aug 29, 2018
P1/2, N=120, Not yet recruiting, Sponsor: Association Pour La Recherche des Th
Trial primary completion date: Jun 2018 --> Apr 2020 Initiation date: Jun 2018 --> Sep 2018
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
Enrollment open: Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients (clinicaltrials.gov) - Aug 29, 2018
P2, N=114, Recruiting, Sponsor: Peking University
Initiation date: Jun 2018 --> Sep 2018 Not yet recruiting --> Recruiting
- | GB241 (rituximab biosimilar) / Nanjing Yoko Biomedical, Walvax
New P3 trial: A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients (clinicaltrials.gov) - Aug 29, 2018
P3, N=360, Not yet recruiting, Sponsor: Nanjing Yoko Biomedical Co., Ltd.
- | ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial: UN-RESARC: Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall (clinicaltrials.gov) - Aug 29, 2018
P2, N=50, Recruiting, Sponsor: Maria Sklodowska-Curie Institute - Oncology Center
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial termination: Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer (clinicaltrials.gov) - Aug 28, 2018
P2, N=15, Terminated, Sponsor: Region Skane
Not yet recruiting --> Recruiting N=30 --> 15 | Active, not recruiting --> Terminated; lack of response
- | Enrollment open, Trial initiation date, Surgery, Metastases: Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum (clinicaltrials.gov) - Aug 28, 2018
P=N/A, N=100, Recruiting, Sponsor: Peking University People's Hospital
N=30 --> 15 | Active, not recruiting --> Terminated; lack of response Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Aug 2018
- | Lartruvo (olaratumab) / Eli Lilly
Trial completion, Trial completion date, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 24, 2018
P1b, N=40, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Aug 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Jul 2018
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P4 trial: SGN35-027: Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma (clinicaltrials.gov) - Aug 23, 2018
P4, N=180, Not yet recruiting, Sponsor: Seattle Genetics, Inc.
- | Rituxan (rituximab) / Roche
Enrollment change: R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Aug 23, 2018
P3, N=138, Terminated, Sponsor: Lymphoma Study Association
Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Jul 2018 N=560 --> 138
- | bortezomib / Generic mfg.
Trial completion: Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma (clinicaltrials.gov) - Aug 23, 2018
P2, N=60, Completed, Sponsor: Lymphoma Study Association
N=560 --> 138 Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion: Mini-CHOP and Rituximab in Patients Aged Over 80 Years (clinicaltrials.gov) - Aug 23, 2018
P2, N=150, Completed, Sponsor: Lymphoma Study Association
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial completion date: Lenalidomide and R-CHOP in B-cell Lymphoma (clinicaltrials.gov) - Aug 23, 2018
P1/2, N=108, Completed, Sponsor: Lymphoma Study Association
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 108 | Trial completion date: Jan 2012 --> Nov 2015
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion: Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide (clinicaltrials.gov) - Aug 22, 2018
P4, N=15, Completed, Sponsor: Texas Tech University Health Sciences Center
Active, not recruiting --> Completed | N=30 --> 108 | Trial completion date: Jan 2012 --> Nov 2015 Active, not recruiting --> Completed
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion date, Trial primary completion date: AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma (clinicaltrials.gov) - Aug 22, 2018
P2, N=9, Active, not recruiting, Sponsor: The Lymphoma Academic Research Organisation
Active, not recruiting --> Completed Trial completion date: Jun 2022 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019
- | New P3 trial: Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 (clinicaltrials.gov) - Aug 21, 2018
P3, N=5000, Recruiting, Sponsor: Martin Schrappe
- | Mepact (mifamurtide) / Takeda
New P2 trial, Metastases: SARCOME13: Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (clinicaltrials.gov) - Aug 21, 2018
P2, N=126, Not yet recruiting, Sponsor: UNICANCER
- | Oncaspar liquid (pegaspargase) / Servier
Trial completion date: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Aug 21, 2018
P3, N=800, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jun 2022 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2019 Trial completion date: Jun 2018 --> Jun 2019
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin (clinicaltrials.gov) - Aug 21, 2018
P=N/A, N=12, Completed, Sponsor: Daniel Rushing
Trial completion date: Jun 2018 --> Jun 2019 Recruiting --> Completed | N=150 --> 12 | Trial completion date: Jun 2018 --> Feb 2018 | Trial primary completion date: Jun 2018 --> Feb 2018
- | Ninlaro (ixazomib) / Takeda
Enrollment open, Trial initiation date, Metastases: NCI-2018-01292: Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (clinicaltrials.gov) - Aug 21, 2018
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | N=150 --> 12 | Trial completion date: Jun 2018 --> Feb 2018 | Trial primary completion date: Jun 2018 --> Feb 2018 Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Aug 2018
- | doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date: 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer (clinicaltrials.gov) - Aug 17, 2018
P2, N=30, Recruiting, Sponsor: Advanced Accelerator Applications
Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Aug 2018 Trial completion date: Apr 2018 --> Dec 2018 | Trial primary completion date: Apr 2018 --> Dec 2018
- | Lartruvo (olaratumab) / Eli Lilly
Trial completion date, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Aug 16, 2018
P1, N=18, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Apr 2018 --> Dec 2018 | Trial primary completion date: Apr 2018 --> Dec 2018 Trial completion date: Sep 2018 --> Mar 2019
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, P2 data, Journal: R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. (Pubmed Central) - Aug 16, 2018
P2
However, most discontinuations occurred during maintenance therapy, suggesting that rituximab over a 4-year span is not feasible for many patients. Nonetheless, this sequential therapeutic strategy resulted in good overall outcomes for patients, including a low incidence of early disease progression.
- | lacnotuzumab (MCS110) / Novartis
Enrollment change, Trial withdrawal: MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer (clinicaltrials.gov) - Aug 16, 2018
P1, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Nonetheless, this sequential therapeutic strategy resulted in good overall outcomes for patients, including a low incidence of early disease progression. N=27 --> 0 | Not yet recruiting --> Withdrawn
- | Nerofe (84AA-API 14AA) / Immune System Key
New P1 trial, Combination therapy, Metastases: Safety and Efficacy of IV Nerofe (clinicaltrials.gov) - Aug 15, 2018
P1b, N=24, Not yet recruiting, Sponsor: Immune System Key Ltd
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Lartruvo (olaratumab) / Eli Lilly
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma (clinicaltrials.gov) - Aug 14, 2018
P1, N=30, Not yet recruiting, Sponsor: University of Miami
N=27 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Jul 2022 --> Oct 2022 | Initiation date: Jul 2018 --> Oct 2018 | Trial primary completion date: Jul 2020 --> Oct 2020
- | Lartruvo (olaratumab) / Eli Lilly
Review, Journal: Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy. (Pubmed Central) - Aug 12, 2018
In this review, we have analyzed the available literature on the development of olaratumab, its clinical utility, and its place in therapy. Based on early-phase clinical trials, olaratumab appears to be a promising agent for the treatment of STS.
- | Bexxar (iodine I 131 tositumomab) / GSK, Rituxan (rituximab) / Roche
Trial completion date: S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 10, 2018
P3, N=571, Active, not recruiting, Sponsor: Southwest Oncology Group
Based on early-phase clinical trials, olaratumab appears to be a promising agent for the treatment of STS. Trial completion date: Jun 2018 --> Jun 2023
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment closed: ATLANTIS: Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (clinicaltrials.gov) - Aug 10, 2018
P3, N=600, Active, not recruiting, Sponsor: PharmaMar
Trial completion date: Jun 2018 --> Jun 2023 Recruiting --> Active, not recruiting
- | thioguanine / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 9, 2018
P2, N=123, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Jul 2018 | Trial primary completion date: Sep 2020 --> Jul 2018
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 9, 2018
P2, N=56, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Jul 2018 | Trial primary completion date: Sep 2020 --> Jul 2018 Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion date, Trial primary completion date: Erythropoietin for Management of Anemia Caused by Chemotherapy (clinicaltrials.gov) - Aug 8, 2018
P2, N=53, Active, not recruiting, Sponsor: Kosin University Gospel Hospital
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Lartruvo (olaratumab) / Eli Lilly
Enrollment closed, Trial completion date, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2018
P1b, N=40, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Completed --> Active, not recruiting |Trial completion date: Jul 2018 --> Jun 2019
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: PETAL: Study of Pembrolizumab Following TACE in Primary Liver Carcinoma (clinicaltrials.gov) - Aug 8, 2018
P1/2, N=26, Recruiting, Sponsor: Imperial College London
Completed --> Active, not recruiting |Trial completion date: Jul 2018 --> Jun 2019 Not yet recruiting --> Recruiting